Epidemiology

You have full text access to this OnlineOpen article

Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case–control study within 35 940 pregnant women

  1. AA Sarfraz1,
  2. SO Samuelsen2,3,
  3. A-L Bruu4,
  4. PA Jenum5,
  5. A Eskild1,6

Article first published online: 16 SEP 2009

DOI: 10.1111/j.1471-0528.2009.02211.x

Issue

BJOG: An International Journal of Obstetrics & Gynaecology

BJOG: An International Journal of Obstetrics & Gynaecology

Volume 116, Issue 11, pages 1492–1498, October 2009

Additional Information

How to Cite

Sarfraz, A., Samuelsen, S., Bruu, A.-L., Jenum, P. and Eskild, A. (2009), Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case–control study within 35 940 pregnant women. BJOG: An International Journal of Obstetrics & Gynaecology, 116: 1492–1498. doi: 10.1111/j.1471-0528.2009.02211.x

Author Information

  1. 1

     Department of Gynecology and Obstetrics and Medical Faculty Division, Akershus University Hospital, Lørenskog, Norway

  2. 2

     Department of Mathematics, University of Oslo, Oslo, Norway

  3. 3

     Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway

  4. 4

     Department of Microbiology, Vestfold Hospital, Tønsberg, Norway

  5. 5

     Department of Microbiology, Asker and Bærum Hospital, Bærum, Norway

  6. 6

     Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway

*Dr A Sarfraz, Department of Gynecology and Obstetrics, Akershus University Hospital, Sykehusveien 27, 1478 Lørenskog, Norway. Email ashi@broadpark.no

Publication History

  1. Issue published online: 16 SEP 2009
  2. Article first published online: 16 SEP 2009
  3. Accepted 7 March 2009.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (94K)

References

  • 1
    Brodlien K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006;260:285–304.
    Direct Link:
  • 2
    Silver RM, Varner MW, Reddy U, Goldenberg R, Pinar H, Conway D, et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007;196:433–4.
  • 3
    Goldenberg R, Thompson C. The infectious origins of stillbirth. Am J Obstet Gynecol 2003;189:861–73.
  • 4
    Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984;2:1033–4.
  • 5
    Remington JS, Klein JO. Infectious Disease of the Fetus and the Newborn Infant, 3rd edn. Philadelphia, PA: W.B. Sanuders, 1990. pp. 779–801.
  • 6
    Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987;316:183–6.
  • 7
    Panum Jensen I, Thorsen P, Jeune B, Møller BR, Vestergaard BF. An epidemic of parvovirus B19 in a population of 3596 pregnant women: a study of sociodemographic and medical risk factors. BJOG 2000;107:637–43.
    Direct Link:
  • 8
    Van Gessel PH, Gaytant MA, Vossen ACTM, Galama JMD, Ursem NTC, Steegers EAP, et al. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: a prospective study. Eur J Obstet Gynecol Reprod Biol 2006;128:46–49.
  • 9
    Yaegashi N, Niinuma T, Chisaka H, Uehara S, Okamura K, Shinkawa O, et al. Serologic study of human parvovirus B19 infection in pregnancy in Japan. J Infect 1999;38:30–35.
  • 10
    De Freitas RB, Wong D, Boswell F, De Miranda MFR, Linhares AC, Shirley J, et al. Prevalence of human parvovirus (B19) and Rubellavirus infections in urban and remote rural areas in northern Brazil. J Med Virol 1990;32:203–8.
    Direct Link:
  • 11
    Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998;91:413–20.
  • 12
    Hall SM. Prospective study of human parvovirus (B19) infection in pregnancy. Br Med J 1990;300:1166–70.
  • 13
    Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. BJOG 1998;105:174–8.
    Direct Link:
  • 14
    Chisaka H, Ito K, Niikura H, Sugawara J, Takano T, Murakami T, et al. Clinical manifestations and outcome of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med 2006;209:277–83.
  • 15
    Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004;24:513–8.
    Direct Link:
  • 16
    Yaegashi N, Niinuma T, Chisaka H, Watanabe T, Uehara S, Okamura K, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 1998;37:28–35.
  • 17
    Kerr JR, O’Neill HJ, Coyle PV, Thompson W. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994;163:65–67.
  • 18
    Kinney JS, Anderson LJ, Farrar J, Strikas RA, Kumar ML, Kliegman RM, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988;157:663–7.
  • 19
    Tolfvenstam T, Papadogiannakis N, Norbeck K, Broliden K. Frequency of human parvovirus B19 infection in inrauterine fetal death. Lancet 2001;357:1494–7.
  • 20
    Jenum PA, Stray-Pedersen B, Melby KK, Kapperud G, Whitelaw A, Eskild A, et al. Incidence of Toxoplasma gondii infection in 35,940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol 1998;36:2900–6.
  • 21
    Statistics in Norway. Statistical Yearbook 1993, Issue 12. Oslo, Norway: Statistics Norway, 1993.
  • 22
    Rasmussen S, Albrechtesen S, Irgens LM, Dalaker K, Maratmann-Moe H, Valtkovic L, et al. Unexplained antepartum fetal death in Norway 1985–97: diagnostic validation and some epidemiologic aspects. Acta Obstet Gynecol Scand 2003;82:109–15.
    Direct Link:
  • 23
    Rasmussen S, Albrechtesen S, Irgens LM, Dalaker K, Maartmann-Moe H, Valtkovic L, et al. Risk factors for unexplained antepartum fetal death in Norway 1967–98. Early Hum Dev 2003;71:39–52.
  • 24
    Eskild A, Jeansson S, Stray-Pedersen B, Jenum PA. Herpes simplex virus type -2 infection in pregnancy: no risk of fetal death: results from a nested case control study within 35,940 women. BJOG 2002;109:1030–5.
  • 25
    Koch WC, Harger JH, Barnstein BBS, Adler SP. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. Pediatr Infect Dis J 1998;17:489–94.
  • 26
    Bruu AL, Nordbø SA. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19. J Clin Microbiol 1995;33:1363–5.
  • 27
    Roger BB. Parvovirus B19: twenty-five years in perspective. Pediatr Dev Pathol 1999;2:296–315.
  • 28
    Gibbs RS. Subclinical infection as a cause of preterm delivery. Pediatr Infect Dis J 1990;9:777–8.
  • 29
    Norwegian Institute of Public Health. New outbreak of erythema infectiosum. MSIS report 8 (March 1st), 1994.
View Full Article (HTML) Get PDF (94K)